文献速递心脑血管急症

P2Y12抑制剂单药与阿司匹林单药用于已确诊动脉粥样硬化患者二级预防:系统评价与荟萃分析

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
PubMed 文献 · Lancet · 2020-01-01
一句话结论在已确诊动脉粥样硬化患者的二级预防中,与阿司匹林单药相比,P2Y12抑制剂单药与心肌梗死风险边缘性降低相关(OR 0.81),但卒中、全因死亡、血管性死亡及大出血风险无差异。

该系统评价与荟萃分析纳入9项随机试验、42108例已确诊脑血管、冠状动脉或外周动脉疾病患者,比较P2Y12抑制剂单药(n=21043)与阿司匹林单药(n=21065)用于二级预防。主要终点为心肌梗死和卒中:P2Y12抑制剂组心肌梗死风险边缘性降低(OR 0.81 [95%CI 0.66-0.99];I²=10.9%),卒中风险无差异(OR 0.93 [0.82-1.06];I²=34.5%)。关键次要终点全因死亡(OR 0.98 [0.89-1.08];I²=0%)和血管性死亡(OR 0.97 [0.86-1.09];I²=0%)无差异,大出血风险亦无差异(OR 0.90 [0.74-1.10];I²=3.9%)。预防一例心肌梗死需治疗244例患者,作者认为鉴于该NNT较高且对全因和血管性死亡无影响,P2Y12抑制剂单药的获益临床意义存疑。

要点

  • 在已确诊脑血管、冠状动脉或外周动脉疾病患者中,P2Y12抑制剂单药较阿司匹林单药心肌梗死风险边缘性降低(OR 0.81 [95%CI 0.66-0.99];I²=10.9%)。
  • P2Y12抑制剂单药与阿司匹林单药的卒中风险无差异(OR 0.93 [95%CI 0.82-1.06];I²=34.5%)。
  • 全因死亡(OR 0.98 [95%CI 0.89-1.08];I²=0%)和血管性死亡(OR 0.97 [95%CI 0.86-1.09];I²=0%)在两组间无差异。
  • 大出血风险在P2Y12抑制剂单药与阿司匹林单药之间无差异(OR 0.90 [95%CI 0.74-1.10];I²=3.9%)。
  • 预防一例心肌梗死需用P2Y12抑制剂单药治疗244例患者;作者认为该获益的临床意义存疑。

适用人群与场景

  • 已确诊脑血管、冠状动脉或外周动脉疾病、需要二级预防抗血小板治疗的患者。
  • 纳入标准为比较P2Y12抑制剂与阿司匹林单药用于二级预防的随机试验;排除标准原文未报告。

研究设计与关键结果

  • 研究类型为系统评价与荟萃分析,纳入9项随机试验,共42108例患者随机分配至P2Y12抑制剂(n=21043)或阿司匹林(n=21065)。
  • 主要终点心肌梗死:P2Y12抑制剂组较阿司匹林组风险边缘性降低(OR 0.81 [95%CI 0.66-0.99];I²=10.9%)。
  • 主要终点卒中:两组无差异(OR 0.93 [95%CI 0.82-1.06];I²=34.5%)。
  • 关键次要终点全因死亡(OR 0.98 [95%CI 0.89-1.08];I²=0%)和血管性死亡(OR 0.97 [95%CI 0.86-1.09];I²=0%)两组无差异。
  • 大出血风险两组无差异(OR 0.90 [95%CI 0.74-1.10];I²=3.9%)。
  • 预防一例心肌梗死需治疗244例患者(NNT=244)。
  • 无论使用何种P2Y12抑制剂,结果一致。

证据类型、等级与局限

  • 证据类型为系统评价与荟萃分析,纳入9项随机试验。
  • 采用随机效应模型计算OR及95%CI,异质性用I²评估。
  • 检索数据库包括PubMed、Embase、BioMedCentral、Google Scholar和Cochrane Central Register of Controlled Trials,检索日期为2019年12月18日,并检索2017至2019年相关科学会议摘要。
  • 研究注册于PROSPERO(CRD42018115037)。

对床旁实践的改变

  • 在已确诊动脉粥样硬化患者的二级预防中,P2Y12抑制剂单药较阿司匹林单药与心肌梗死风险边缘性降低相关,但作者认为鉴于NNT为244且对全因和血管性死亡无影响,该获益的临床意义存疑。
  • P2Y12抑制剂单药与阿司匹林单药在卒中、全因死亡、血管性死亡及大出血风险方面无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention.

METHODS: In this systematic review and meta-analysis, all randomised trials comparing P2Y12 inhibitor with aspirin monotherapy for secondary prevention in patients with cerebrovascular, coronary, or peripheral artery disease were evaluated for inclusion. On Dec 18, 2019, we searched PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register of Controlled Trials. Additionally, we reviewed references from identified articles and searched abstracts from 2017 to 2019 presented at relevant scientific meetings. Data about year of publication, inclusion and exclusion criteria, sample size, baseline patients' features including the baseline condition determining study inclusion (ie, cerebrovascular, coronary, or peripheral artery disease), P2Y12 inhibitor type and dosage, aspirin dosage, endpoint definitions, effect estimates, follow-up duration, and percentage of patients lost to follow-up were collected. Odds ratios (ORs) and 95% CIs were used as metric of choice for treatment effects with random-effects models. Co-primary endpoints were myocardial infarction and stroke. Key secondary endpoints were all-cause death and vascular death. Heterogeneity was assessed with the I2 index. This study is registered with PROSPERO (CRD42018115037).

FINDINGS: A total of nine randomised trials were identified and included in this study, and 42 108 patients randomly allocated to a P2Y12 inhibitor (n=21 043) or aspirin (n=21 065) were included in our analyses. Patients who received a P2Y12 inhibitor had a borderline reduction for the risk of myocardial infarction compared with those who received aspirin (OR 0·81 [95% CI 0·66-0·99]; I2=10·9%). Risks of stroke (OR 0·93 [0·82-1·06]; I2=34·5%), all-cause death (OR 0·98 [0·89-1·08]; I2=0%), and vascular death (OR 0·97 [0·86-1·09]; I2=0%) did not differ between patients who received a P2Y12 inhibitor and those who received aspirin. Similarly, the risk of major bleeding (OR 0·90 [0·74-1·10]; I2=3·9%) did not differ between patients who received a P2Y12 inhibitor and those who received aspirin. The number needed to treat to prevent one myocardial infarction with P2Y12 inhibitor monotherapy was 244 patients. Findings were consistent regardless of the type of P2Y12 inhibitor used.

INTERPRETATION: Compared with aspirin monotherapy, P2Y12 inhibitor monotherapy is associated with a risk reduction for myocardial infarction and a comparable risk of stroke in the setting of secondary prevention. The benefit of P2Y12 inhibitor monotherapy is of debatable clinical relevance, in view of the high number needed to treat to prevent a myocardial infarction and the absence of any effect on all-cause and vascular mortality.

FUNDING: Italian Ministry of Education.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020. PMID: 32386592. doi:10.1016/S0140-6736(20)30315-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。